We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy.
- Authors
Chan, Wei Yee; Sanchez, Emilie; Chavda, Selina J.; Lecat, Catherine S. Y.; Ainley, Louise; Xu, Ke; Wisniowski, Brendan; Mahmood, Shameem; Papanikolaou, Xenofon; Kyriakou, Charalampia; Sive, Jonathan; Wechalekar, Ashutosh; Popat, Rakesh; Rabin, Neil; Lee, Lydia; Nastouli, Eleni; Yong, Kwee L.
- Abstract
Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy Keywords: antibody response; COVID-19 disease; multiple myeloma; plasma cell disorders; SARS-CoV-2 EN antibody response COVID-19 disease multiple myeloma plasma cell disorders SARS-CoV-2 857 861 5 09/02/21 20210901 NES 210901 Patients with multiple myeloma and related plasma cell disorders (PCD) are considered extremely vulnerable to SARS-CoV-2 infection due to disease-related impaired humoral and cellular immunity as well as receipt of immunosuppressive therapy.1 Overall mortality from COVID-19 disease in 650 PCD patients across 10 countries was 33%.2 Poor outcomes from COVID-19 disease have resulted in recommendations for modifications to systemic anti-cancer therapy (SACT) to reduce the risk of infection whilst balancing the potential complications of untreated PCD.3 With the rollout of the COVID-19 vaccines, there is urgent need to understand seroconversion in immunocompromised patients for ongoing patient management and recommendation. Positive antibody test post PCR-confirmed infection occurred at a median of 86-5 days compared to 30-5 days for those who tested negative, suggesting a delayed response compared to the general population of 14-28 days.12 Our study and analyses are limited by small number of seropositive patients and those undergoing antibody testing post PCR-diagnosed COVID-19 disease. Patients with positive SARS-CoV-2 antibody test categorised by PCR-positive patients and unexpected antibody test positive patients.
- Subjects
PLASMA cell diseases; SARS-CoV-2; ANTIBODY formation; INFECTION; COVID-19; MULTIPLE myeloma
- Publication
British Journal of Haematology, 2021, Vol 194, Issue 5, p857
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17441